natgillin/translations-raw huggingface dataset:
YENTREVE and Prior Continence Surgery: There are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery.
Zdravilo YENTREVE in predhodno kirurško zdravljenje inkontinence: omejeni podatki kažejo, da koristi zdravila YENTREVE pri bolnicah s stresno urinsko inkontinenco, ki so bile predhodno operirane zaradi inkontinence, niso zmanjšane.
6 Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials.
6Ocenjena pogostost pojava neželenih učinkov v postmarketinških študijah; teh učinkov v s placebom kontroliranih kliničnih študijah niso opazili.
Weight decrease Weight increase Blood cholesterol increased Blood creatine
Preiskave zmanjšanje telesne mase povečanje telesne mase zvišanje krvnega holesterola zvišanje krvne kreatininfosfokinaze zvišanje krvnega kalija
YENTREVE should not be used for children and adolescents under 18 years.
Zdravila YENTREVE pri otrocih in mladostnikih, mlajših od 18 let, ne smemo uporabljati.
YENTREVE is a medicine to be taken by mouth to treat Stress Urinary Incontinence (SUI) in women.
YENTREVE je zdravilo, ki ga jemljemo peroralno, za zdravljenje stresne urinske inkontinence (SUI), pri ženskah.
Your doctor will tell you if you should be taking YENTREVE.
Vaš zdravnik vam bo povedal, če smete jemati zdravilo YENTREVE.
CNS medicinal products: Caution is advised when YENTREVE is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zdravila CŽS: če se zdravilo YENTREVE jemlje v kombinaciji z drugimi centralno delujočimi zdravili ali snovmi, vključno z alkoholom in pomirjevali (benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbitalom, sedativnimi antihistaminiki), priporočamo previdnost.
YENTREVE should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures.
Zdravilo YENTREVE moramo pri bolnicah z manijo v anamnezi ali diagnozo bipolarne motnje in/ali epileptičnimi napadi uporabljati previdno.
• feeling nervous, difficulty concentrating, changes in sense of taste, poor sleep quality
• občutek živčnosti, težave s koncentracijo, spremenjeno okušanje stvari, slaba kvaliteta spanja
• feeling of dizziness or “spinning” (vertigo)
• občutek omotice ali vrtoglavice (vertiga)
Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment.
Farmakokinetični podatki o duloksetinu so pri bolnikih z blago ali zmerno okvarjenim delovanjem ledvic omejeni.
• passing bright red blood in your stools, inflammation of the large intestine (leading to diarrhoea)
• svetlo rdeča kri v blatu, vnetje debelega črevesa (ki povzroča drisko)
Female mice receiving duloxetine for 2 years had an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic microsomal enzyme induction.
Vzročni mehanizem in klinični pomen nista znana.Mišje samice, ki so prejemale duloksetin 2 leti, so imele povišano incidenco hepatocelularnih adenomov in karcinomov samo pri visokem odmerku (144 mg/kg/dan), vendar za te velja, da se pojavijo sekundarno zaradi indukcije jetrnih mikrosomskih encimov.
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with YENTREVE (see section 4.4).
Antibiotik linezolid je reverzibilen, neselektiven MAOI in ga bolniki, zdravljeni z zdravilom YENTREVE, ne smejo prejemati (glejte poglavje 4.4).
Quality of Life: Incontinence Quality of Life (I-QOL) questionnaire scores were significantly improved in the duloxetine-treated patient group compared with the placebo-treated group (9.2 versus 5.9 score improvement, p<0.001).
(Incontinence Quality of Life, I-QOL) so bili v skupini bolnic, zdravljenih z duloksetinom, v primerjavi s tistimi, ki so prejemale placebo, značilno izboljšani (izboljšanje števila točk 9,2 v primerjavi s 5,9, p < 0,001).
Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8).
Spolna disfunkcija Selektivni zaviralci ponovnega privzema serotonina (SSRI)/zaviralci ponovnega privzema serotonina in noradrenalina (SNRI) lahko povzročijo simptome spolne disfunkcije (glejte poglavje 4.8).
Liver disease resulting in hepatic impairment (see section 5.2).
Obolenje jeter, katerega posledica je okvarjeno delovanje jeter (glejte poglavje 5.2).
After an intravenous dose the plasma clearance of duloxetine ranges from 22 l/hr to 46 l/hr (mean of 36 l/hr).
Po intravenskem odmerku plazemski očistek duloksetina zavzema vrednosti od 22 l/h do 46 l/h (povprečno 36 l/h).
YENTREVE must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min; see section 4.3).
Zdravila YENTREVE ne smemo uporabljati pri bolnikih s hudo okvarjenim delovanjem ledvic (očistek kreatinina < 30 ml/min, glejte poglavje 4.3).
You must wait at least 14 days after you have stopped taking an MAOI before you can take YENTREVE.
Po prenehanju jemanja MAOI morate počakati vsaj 14 dni, preden lahko vzamete zdravilo YENTREVE.
Based on the half-life of duloxetine, at least 5 days should be allowed after stopping YENTREVE before starting an MAOI (see section
Na podlagi razpolovnega časa duloksetina mora po prenehanju jemanja zdravila YENTREVE preteči vsaj 5 dni pred začetkom jemanja MAOI
Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine.
kot tudi CYP1A2 katalizirata tvorbo dveh poglavitnih presnovkov glukuronidnega konjugata 4hidroksi duloksetina in sulfatnega konjugata 5-hidroksi 6-metoksi duloksetina.
Oy Eli Lilly Finland Ab Puh/Tel: +358-(0) 9 85 45 250
Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: +358 (0)9 8545 250
YENTREVE must not be used in women with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).
Zdravila YENTREVE ne smemo uporabljati pri ženskah z obolenjem jeter, katerega posledica je okvarjeno delovanje jeter (glejte poglavje 4.3 in 5.2).
The efficacy of YENTREVE has not been evaluated for longer than 3 months in placebo-controlled studies.
Učinkovitosti zdravila YENTREVE v študijah, kontroliranih s placebom, niso vrednotili dlje kot 3 mesece.
YENTREVE 40 mg is available in packs of 28, 56, 98 and 140 hard gastro-resistant capsules and in a multipack containing 196 (2 packs of 98) hard gastro-resistant capsules.
Zdravilo YENTREVE 40 mg je na voljo v pakiranju po 28, 56, 98 in 140 trdih gastrorezistentnih kapsul in v večjem pakiranju, ki vsebuje 196 (2 pakiranji po 98) trdih gastrorezistentnih kapsul.
Therefore YENTREVE should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).
Zato zdravila YENTREVE ne smemo dajati skupaj z močnimi zaviralci CYP1A2, kot je fluvoksamin (glejte poglavje 4.4).
If your doctor thinks that you no longer need YENTREVE he or she will ask you to reduce your dose over 2 weeks.
Če bo vaš zdravnik menil, da zdravila YENTREVE ne potrebujete več, vam bo naročil/naročila, da
In pre/postnatal toxicity study in the rat, duloxetine induced adverse behavioural effects in the offspring at systemic exposure levels below maximum clinical exposure (AUC).
V študiji pre- in postnatalne toksičnosti pri podganah je duloksetin povzročil neželene vedenjske učinke pri mladičih ob ravneh sistemskih izpostavitev, manjših od maksimalne klinične izpostavitve (AUC).
YENTREVE is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI).
YENTREVE je zdravilo, pri ženskah indicirano za zdravljenje zmerne do hude stresne urinske inkontinence (Stress Urinary Incontinence, SUI).
Hypertension3,7 Flushing
Žilne bolezni hipertenzija3,7
Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.
Na podlagi študij in vitro veljajo presnovki duloksetina v krvnem obtoku za farmakološko nedejavne.
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouth fatigue and constipation.
Neželeni učinki, o katerih so pri bolnicah, zdravljenih z zdravilom YENTREVE v kliničnih preskušanjih o SUI in drugih boleznih spodnjih sečil, najpogosteje poročali, so bili slabost, suha usta,
• vomiting blood, or black tarry stools (faeces), gastroenteritis, inflammation of the mouth, burping, difficulty swallowing, breaking wind, bad breath
• več zehanja • bruhanje krvi ali črno blato, gastroenteritis, vnetje ust, riganje, težave pri požiranju, vetrovi, slab zadah
Hard gastro-resistant capsule.
trda gastrorezistentna kapsula
EU/1/04/280/002(28 hard gastro-resistant capsules) EU/1/04/280/003 (56 hard gastro-resistant capsules) EU/1/04/280/004 (98 hard gastro-resistant capsules) EU/1/04/280/005 (140 hard gastro-resistant capsules)
EU/1/04/280/002 (28 trdih gastrorezistentnih kapsul) EU/1/04/280/003 (56 trdih gastrorezistentnih kapsul) EU/1/04/280/004 (98 trdih gastrorezistentnih kapsul) EU/1/04/280/005 (140 trdih gastrorezistentnih kapsul)
How to take YENTREVE
KAKO JEMATI ZDRAVILO YENTREVE
Each capsule may contain up to 37 mg sucrose.
Ena kapsula lahko vsebuje 37 mg saharoze.
YENTREVE should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors - MAOIs (see section 4.5).
Zdravila YENTREVE ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze - MAOI (glejte poglavje 4.5).
What YENTREVE is and what it is used for What you need to know before you take YENTREVE How to take YENTREVE
Kaj je zdravilo YENTREVE in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo YENTREVE Kako jemati zdravilo YENTREVE
• difficulty or inability to pass urine, needing to pass more urine than normal, having a decreased urine flow
• težave ali nezmožnost odvajanja urina, bolj pogosto odvajanje urina, slabši curek urina
• (itchy) rash, night sweats, hives, cold sweats, increased tendency to bruise
• (srbeč) izpuščaj, nočno potenje, koprivnica, hladen znoj, povečano nagnjenje k modricam
Each capsule may contain up to 74 mg sucrose.
Ena kapsula lahko vsebuje 74 mg saharoze.
28 hard gastro-resistant capsules 56 hard gastro-resistant capsules 98 hard gastro-resistant capsules 140 hard gastro-resistant capsules
28 trdih gastrorezistentnih kapsul 56 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul 140 trdih gastrorezistentnih kapsul
As the safety of duloxetine in infants is not known, the use of YENTREVE while breast-feeding is not recommended.
Ker varnost uporabe duloksetina pri dojenčkih ni znana,
Ask your pharmacist how to throw away of medicines you no longer use.
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
YENTREVE 40 mg is available in packs of 28, 56, 98, 140 and 196 (2 x 98) capsules.
Zdravilo YENTREVE 40 mg je na voljo v pakiranjih po 28, 56, 98, 140 in 196 (2 x 98) kapsul.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
IMETNIK DOVOLJENJA ZA PROMET Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
YENTREVE and Pelvic Floor Muscle Training (PFMT): During a 12-week blinded, randomised, controlled study, YENTREVE demonstrated greater reductions in IEF compared with either placebo treatment or with PFMT alone.
Zdravilo YENTREVE in trening mišic medeničnega dna (Pelvic Floor Muscle Training, PFMT): v 12tedenski slepi, randomizirani, kontrolirani študiji je zdravilo YENTREVE pokazalo večja znižanja IEF
Edible ink: synthetic black iron oxide (E172), propylene glycol, shellac.
Užitno črnilo: sintetični črni železov oksid (E172), propilen glikol, šelak.
Check with your doctor if you are already taking other medicines containing duloxetine.
če že jemljete druga zdravila, ki vsebujejo duloksetin.
Capsule shell: gelatin, sodium lauryl sulfate, titanium dioxide (E171), indigo carmine (E132), red iron oxide and yellow iron oxide, edible black ink.
Ovojnica kapsule: želatina, natrijev lavrilsulfat, titanov dioksid (E171), indigotin (E132), rdeči železov oksid in rumeni železov oksid, užitno črno črnilo.
Eli Lilly and Company Limited Tel: + 44-(0) 1256 315000
United Kingdom Eli Lilly and Company Limited Tel: +44 (0) 1256 315999
• feeling sick (nausea), dry mouth, constipation • fatigue
• občutek slabosti (navzea), suha usta, zaprtje
No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min).
Pri bolnicah z blago do zmerno okvarjenim delovanjem ledvic (očistek kreatinina 30 do 80 ml/min)
Also, you need to wait at least 5 days after you stop taking YENTREVE before you take a MAOI.
Tudi po prenehanju jemanja zdravila YENTREVE morate počakati vsaj 5 dni, preden lahko vzamete MAOI.
Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Zaviralci monoaminooksidaze (MAOI): zaradi nevarnosti za serotoninski sindrom duloksetina ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze
Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing duloxetine in patients with increased intraocular pressure, or those at risk of acute narrowangle glaucoma.
V povezavi z duloksetinom so poročali o midriazi, zato je pri predpisovanju bolnicam s povišanim intraokularnim tlakom ali s tveganjem za akutni glavkom z zaprtim zakotjem potrebna previdnost.
The use of YENTREVE while breastfeeding is not recommended.
Uporabo zdravila YENTREVE v času dojenja odsvetujemo.
The efficacy of YENTREVE is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT).
Učinkovitost zdravila YENTREVE je ojačana, če jo uporabljamo sočasno z izvajanjem programa, imenovanega trening mišic medeničnega dna.
• trouble sleeping, feeling agitated, less sex drive, anxiety, difficulty sleeping
• težave s spanjem, občutek razdraženosti, manjša želja po spolnosti, anksioznost, slaba kvaliteta spanja
• muscle pain, muscle tightness, muscle spasm, contraction of the jaw muscle
• mišična bolečina, mišična napetost, mišični krč, krčenje čeljustne mišice
No malformations were observed in another study testing a higher dose of a different salt of duloxetine.
V drugi študiji, v kateri so preučevali višje odmerke različnih soli duloksetina, niso opazili nobenih malformacij.
The following are reasons why YENTREVE may not be suitable for you.
Opozorila in previdnostni ukrepi Spodaj so našteti razlogi, zaradi katerih morda zdravilo YENTREVE za vas ni ustrezno.
• Stevens-Johnson syndrome (serious illness with blistering of the skin, mouth, eyes and genitals),
• Stevens-Johnsonov sindrom (resna bolezen z mehurji na koži, ustih, očeh in genitalijah), resne alergične reakcije, ki povzročijo otekanje obraza ali grla (angioedem), občutljivost na sončno svetlobo
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events).
Depresija je povezana z večjim tveganjem za pojav samomorilnih misli,
98 hard gastro-resistant capsules.
98 trdih gastrorezistentnih kapsul
The 40 mg capsules are orange and blue and are printed with '40 mg' and the code ‘9545'.
40 mg kapsule so oranžne in modre z vtisnjenim napisom ‘40 mg' in oznako ‘9545'.
Multipack: 196 (2 packs of 98 hard gastro-resistant capsules)
FARMACEVTSKA OBLIKA IN VSEBINA Večje pakiranje: 196 (-2 pakiranji po 98 trdnih gastrorezistentnih kapsul) .
The 20 mg capsules are blue and are printed with '20 mg' and the code ‘9544'.
20 mg kapsule so modre z vtisnjenim napisom ‘20 mg' in oznako ‘9544'.
YENTREVE contains the active substance duloxetine.
Zdravilo YENTREVE vsebuje učinkovino duloksetin.
• dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.
• omotica, ščemenje (občutek zbadanja z iglami) ali občutki, podobni električnemu šoku (predvsem v glavi), motnje spanja (žive sanje, nočne more, nezmožnost spanja), utrujenost, zaspanost, občutek nemira ali razburjenosti, občutek strahu, slabost ali bruhanje, tresenje, glavoboli, bolečina v mišicah, občutek razdraženosti, driska, prekomerno znojenje ali vrtoglavica
In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC).
V študiji embriotoksičnosti pri zajcih, pri sistemskih izpostavitvah, nižjih od maksimalne klinične izpostavitve (AUC), so opazili večjo incidenco kardiovaskularnih in skeletnih malformacij.
YENTREVE 20 mg YENTREVE 20 mg is available in packs of 28, 56 and 98 hard gastro-resistant capsules.
YENTREVE 20 mg Zdravilo YENTREVE 20 mg je na voljo v pakiranju po 28, 56 in 98 trdih gastrorezistentnih kapsul.
• headache, dizziness, feeling sluggish, feeling sleepy, tremor, numbness, including numbness,
• glavobol, omotica, občutek nezbranosti, občutek zaspanosti, tresenje, otrplost, vključno z otrplostjo, zbadanjem ali mravljinčasto kožo • zamegljen vid
YENTREVE 20 mg is available in packs of 28, 56 and 98 capsules.
Zdravilo YENTREVE 20 mg je na voljo v pakiranjih po 28, 56 in 98 kapsul.
Medicinal products metabolised by CYP1A2: The pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily).
Učinki duloksetina na druga zdravila Zdravila, ki jih presnavlja CYP1A2: sočasno dajanje duloksetina (60 mg dvakrat dnevno) ni značilno vplivalo na farmakokinetiko teofilina, substrata CYP1A2.
• weakness, shivering
• šibkost, drgetanje
Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant
Podatki iz kliničnih preskušanj kažejo, da pri mlajših odraslih osebah (mlajših od 25 let) z motnjami razpoloženja med zdravljenjem z antidepresivi obstaja večje tveganje za pojav samomorilnega vedenja.
The concomitant use of YENTREVE with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4).
Sočasno uporabo zdravila YENTREVE s selektivnimi reverzibilnimi MAOI, kakršen je npr. moklobemid, odsvetujemo (glejte poglavje 4.4).
Medicines that increase the level of serotonin: Triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), SNRIs (such as venlafaxine), tricyclic antidepressants (such as clomipramine, amitriptyline), pethidine, St John's Wort and MAOIs (such as moclobemide and linezolid).
Zdravila, ki zvišajo nivo serotonina: triptani, tramadol, triptofan, SSRI (kot sta paroksetin in fluoksetin), SNRI (kot je venlafaksin), triciklični antidepresivi (kot sta klomipramin, amitriptilin), petidin, šentjanževka in MAOI (kot sta moklobemid in linezolid).Ta zdravila povečajo tveganje za neželene učinke; če se pojavi kakršenkoli neobičajen simptom ob jemanju katerega od teh zdravil skupaj z zdravilom YENTREVE, obiščite svojega zdravnika.
Do not take more than the daily amount of YENTREVE that has been prescribed for you in one day.
Ne zaužijte več zdravila YENTREVE v enem dnevu, kot vam je bilo predpisano.
Monoamine oxidase inhibitors (MAOIs): You should not take YENTREVE if you are taking or have recently taken (within the last 14 days) an antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Zaviralci monoaminooksidaze (MAOI): zdravila YENTREVE ne smete jemati skupaj z drugim zdravilom za zdravljenje depresije imenovanim zaviralec monoaminooksidaze (MAOI) ali v 14 dneh po prenehanju jemanja MAOI.
Convulsions1,6 Myoclonus Akathisia6
mioklonus akatizija6
Orthostatic hypotension2 Peripheral coldness
rdečica sinkopa2 zvišan krvni tlak hipertenzivna kriza ortostatska hipotenzija2 hladni periferni deli
- are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6) - have liver disease - have severe kidney disease - are taking or have taken within the last 14 days, another medicine known as a monoamine oxidase inhibitor (MAOI) (see ‘Other medicines and YENTREVE') - are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or enoxacin which are used to treat some infections
NE jemljite zdravila YENTREVE, če: - ste alergični (preobčutljivi) na duloksetin ali katerokoli pomožno snov tega zdravila (navedeno v poglavju 6) - imate obolenje jeter imate hudo obolenje ledvic - jemljete ali ste v zadnjih 14 dneh jemali drugo zdravilo, imenovano zaviralec monoaminooksidaze (MAOI) (glejte »Druga zdravila in zdravilo YENTREVE«)
Metabolism and nutrition disorders Appetite decreased
Presnovne in prehranske motnje zmanjšanje apetita dehidracija hiperglikemija
Medicines that cause sleepiness: These include medicines prescribed by your doctor including benzodiazepines, strong painkillers, antipsychotics, phenobarbital and sedative antihistamines.
V to skupino denimo uvrščajo benzodiazepine, močna zdravila proti bolečinam, antipsihotike, fenobarbital in sedativne antihistaminike.
Talk to your doctor before you take Yentreve if you: - are taking medicines to treat depression (see ‘Other medicines and YENTREVE') - are taking St. John's Wort, a herbal treatment (Hypericum perforatum) - have kidney disease - have had seizures (fits) - have had mania - suffer from bipolar disorder - have eye problems, such as certain kinds of glaucoma (increased pressure in the eye) - have a history of bleeding disorders (tendency to develop bruises), especially if you are pregnant (see ‘Pregnancy and breast-feeding‘) - are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly) - are currently being treated with another medicine which may cause liver damage.
- ste v preteklosti imeli motnje strjevanja krvi (nagnjenost k razvoju podplutb), sploh če ste noseči (glejte »Nosečnost in dojenje«) - imate tveganje za nizek nivo natrija (če na primer jemljete diuretike, sploh če ste starejši) - se trenutno zdravite z drugimi zdravili, ki lahko povzročijo poškodbo jeter
There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs), including duloxetine.
Pri selektivnih zaviralcih prevzema serotonina (selective serotonin reuptake inhibitors, SSRI) in selektivnih zaviralcih prevzema noradrenalina (selectivenoradrenaline reuptake inhibitors, SNRI),
• abnormal periods, including heavy, painful, irregular or prolonged periods, unusually light or missed periods, abnormal production of breast milk
• neobičajna menstruacija, vključno z močno, bolečo, neredno ali podaljšano menstruacijo, neobičajna blaga ali spuščena menstruacija, nenormalno nastajanje mleka v dojkah pri moških in ženskah • prekomerna krvavitev iz nožnice kmalu po porodu (poporodna krvavitev)
Suicidal behaviour5,6
konvulzije1,6
Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function (e.g. NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.
Pri bolnicah, ki jemljejo sredstva proti strjevanju krvi in/ali druga zdravila, za katera je znano, da vplivajo na delovanje trombocitov (npr. nesteroidne protivnetne učinkovine (NSAID) ali acetilsalicilna kislina